FDA Sets Termination Date for Invivyd’s PEMGARDA Emergency Use Authorization

Key Facts

In a move reflecting the broader U.S. government transition away from pandemic-era health measures, Invivyd has been notified by the FDA that the Emergency Use Authorization (EUA) for its COVID-19 antibody, PEMGARDA, will terminate on June 29, 2027. This decision stems from the general conclusion of the COVID-19 emergency use declaration, which impacts all medical products currently operating under such mandates. According to reports, the 12-month advance notice is intended to provide a structured pathway for the company to transition toward full regulatory approval.

Invivyd operates in a specialized biotech niche where companies are increasingly pressured to realign strategies as emergency funding and fast-track authorizations expire. Peers such as AstraZeneca and Regeneron have similarly navigated the shift toward standard regulatory pathways for their antibody treatments. Per market data, small-to-mid-cap biotech firms often experience heightened volatility when primary product regulatory frameworks shift, particularly as they approach the deadlines for filing formal Biologics License Applications (BLA).

Investors should closely watch the company's progress in meeting full licensure requirements before the June 2027 deadline to ensure uninterrupted commercial availability. Regarding upcoming catalysts, the market is awaiting the Dallas Fed Manufacturing Index on June 29, 2026, followed by the JOLTs Job Openings report on June 30, 2026, both of which may influence broader risk sentiment across the U.S. healthcare and equity sectors.